Navigation Links
Hollis-Eden Announces Cancellation of Acute Radiation Syndrome RFP,by Department of Health and Human Services

SAN DIEGO--(BUSINESS WIRE)--Mar 8, 2007 - Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) today announced that it was informed late Wednesday, March 07, 2007, by the Department of Health & Human Services (HHS) that NEUMUNE(R), the Company's product candidate for the treatment of Acute Radiation Syndrome (ARS) was found technically unacceptable and was no longer in the competitive range for the Request for Proposal (RFP) No. DHHS-ORDC-DDA-05-12 entitled, "Medical Countermeasures to Mitigate or Treat Neutropenia Alone or in Combination with Co-Morbidities Associated with Acute Radiation Syndrome (ARS)." No other rationale was provided. Further, Hollis-Eden was notified that HHS had cancelled the solicitation in its entirety.

The Company was surprised by this decision by HHS. In June 2006, based on HHS' evaluation of the Company's technical and cost proposal, HHS informed the Company that its proposal for NEUMUNE was within the competitive range. HHS reaffirmed this decision in October 2006, and Hollis-Eden believes that as of that time its proposal was the only proposal still being considered by HHS. Since that time, HHS has not requested any additional safety or efficacy data on NEUMUNE that had not previously been provided in detailed or summary form. Therefore, the Company is unable to comprehend how NEUMUNE can no longer meet the technical requirements of the solicitation.

"Given the nature and stage of our communications with HHS regarding our original ARS proposal and subsequent revisions, this decision by HHS to exclude our proposal and cancel the RFP is shocking and difficult to understand," stated Richard B. Hollis, Chairman and Chief Executive Officer of Hollis-Eden. "While we will attempt to gain a better understanding from HHS why this determination was made, we clearly met all of the very detailed requirements of the solicitation. NEUMUNE is the only agent ever to have shown the ability to
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:3/27/2015)... The Temple Health & Bioscience District (THBD) today ... at 1802 South First St. in the Temple Medical and ... City of Temple to receive funding for ... Texas Veterans Health Care System, the new facility will enable ... biotechnology and life science companies. ...
(Date:3/27/2015)... -- Zimmer Holdings, Inc. (NYSE and SIX: ZMH) is launching ... Available in both small (6mm) and large ... System from Zimmer is a modular system that offers surgeons ... XtraFix System allows surgeons to eliminate steps, as well ... in saved time, costs and overall team effort. ...
(Date:3/27/2015)... 27, 2015  Valeant Pharmaceuticals International, Inc. (NYSE: ... its previously announced registered offering of common shares in ... Pursuant to the Offering, the Company issued 7,286,432 common ... aggregate gross proceeds of approximately $1.45 billion. On March ... and Exchange Commission a final prospectus supplement to its ...
Breaking Medicine Technology:Temple Health & Bioscience District Relocates, Offers Office And Lab Space To Biotech Companies 2Zimmer Debuts New Modular External Fixation System 2Zimmer Debuts New Modular External Fixation System 3Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3
... High-Risk Infants Versus,Current Standard of Care and ... Lower Respiratory Infections -, TORONTO, May 08, ... results from a large prospective trial,conducted for ... compared motavizumab, the investigational monoclonal antibody,(MAb) also ...
... WIRE)--May 8, 2007 - AVANIR,Pharmaceuticals (NASDAQ:AVNR) today ... and improvements in patient-centered outcomes in,patients with ... investigational drug Zenvia(TM) (dextromethorphan /,quinidine) will be ... International Congress on Neuropathic Pain, being held ...
Cached Medicine Technology:MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 2MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 3MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 4MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 5MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 6MedImmune Announces Positive Clinical Results at PAS Annual Meeting,From Large Prospective Trial in Prevention of Serious RSV Disease 7AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at Second International Congress on,Neuropathic Pain 2AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at Second International Congress on,Neuropathic Pain 3AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at Second International Congress on,Neuropathic Pain 4
(Date:3/29/2015)... Birmingham, Lake Orion, Clarkston, Metamora, MI. (PRWEB) March 29, ... affiliated with Beaumont Hospital , offers comprehensive endometriosis ... now offer patients in that area a closer hospital ... St. Joseph Mercy Oakland and McLaren Oakland. ... tissue that normally lines the inside of the uterus ...
(Date:3/29/2015)... March 30, 2015 Telerad RxDx ... the coveted NABH Accreditation on 11th January 2015. ... Hospitals and Healthcare Providers) comes as a true ... standards of Telerad RxDx., With Telerad RxDx being ... accredited for NABH, marks a major achievement and ...
(Date:3/29/2015)... The Claudia Cohen Research Foundation ... announce today that Dr. Beth Y. Karlan has been ... Research Foundation Prize for Outstanding Gynecologic Researcher. The $50,000 ... Oncology 46th Annual Meeting on Women's Cancer in Chicago. ... Cancer Program at the Samuel Oschin Comprehensive Cancer Institute ...
(Date:3/29/2015)... The federal court overseeing hundreds ... in the U.S. District Court, Northern District of ... Conference for April 21st at 1:30 p.m. Court ... progress of product liability claims filed on behalf ... and other cardiovascular complications due to their use ...
(Date:3/29/2015)... (PRWEB) March 29, 2015 Youth Villages ... counties in Oregon to assess the feasibility of implementing ... emotional and behavioral problems and their families. , Third ... select participants that will be provided technical assistance throughout ... counties join six other national awardees chosen by Third ...
Breaking Medicine News(10 mins):Health News:Women's Excellence Affiliates with Beaumont Hospital, Treats Endometriosis 2Health News:NABH Accreditation for Telerad RxDx – Whitefield. 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 3Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 4Health News:Federal Court Overseeing Testosterone Treatment Lawsuits Schedules April Case Management Conference 2Health News:Federal Court Overseeing Testosterone Treatment Lawsuits Schedules April Case Management Conference 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 2Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 4
... , Jan. 15 Healthcare Data Services (HDS) ... Quality Care Alliance (NEQCA), Tufts Medical Center Physicians Organization, to ... their proprietary HDS Analyst(SM) tool. The contract was established following ... the data monitoring needs of NEQCA and Tufts Medical Center ...
... Social status is intimately linked with health-related risk factors. ... , Thomas Lampert, of the Robert Koch Institute (RKI) ... and obesity are associated with social status (Dtsch Arztebl ... of social status-specific differences stemmed from the RKI,s Telephone ...
... in adulthood, researchers say , FRIDAY, Jan. 15 (HealthDay ... memory defects in adulthood, new research in rats suggests. ... to develop learning and memory deficits. It hasn,t been ... help the kids grow taller -- can help fend ...
... RALEIGH, N.C. , Jan. 15 PRA International, a ... client-facing portal into Oracle® Remote Data Capture (RDC) for its early ... and the United States . Through the portal, clients ... The portal provides sponsors with the ability to review all entered ...
... reasonable to obtain a histological diagnosis before treating patients ... to undergo surgery. As the pancreas is a deep ... a challenge for the physician to obtain an adequate ... masses has been proved to be a safe and ...
... ... co-founder and Chief Executive Officer Sean Lynch will be speaking at the McGuire ... The event takes place on February 11, 2010 at the Palmer House ... the conference, addressing managing costs and improving revenues in healthcare services. , ...
Cached Medicine News:Health News:Healthcare Data Services (HDS) Announces Contract with the New England Quality Care Alliance (NEQCA), the Physicians Organization of Tufts Medical Center 2Health News:Healthcare Data Services (HDS) Announces Contract with the New England Quality Care Alliance (NEQCA), the Physicians Organization of Tufts Medical Center 3Health News:PRA International Rolls out Client Access to Oracle(R) RDC for Early Phase Studies 2Health News:Anesthesia Healthcare Partners CEO to Speak at Upcoming Healthcare Conference to Offer Insight on Managing Costs in Healthcare Services 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: